Publications by authors named "Ankita P Sankar"
Cancer Res Commun
March 2024
Article Synopsis
- The study investigates a new protein, αEGFR-E-P125A, designed to inhibit blood vessel formation (angiogenesis) and a cancer-associated process called vasculogenic mimicry (VM) in triple-negative breast cancer (TNBC).
- RNA sequencing of TNBC cells showed that VM activation is linked to specific signaling pathways and that treatment with αEGFR-E-P125A effectively downregulates these pathways.
- In laboratory and animal models, αEGFR-E-P125A demonstrated significant reduction in tumor growth and metastasis, highlighting its potential as a therapeutic strategy for targeting aggressive forms of breast cancer.
Article Synopsis
- Triple negative breast cancer (TNBC) is a tough-to-treat cancer subtype that often leads to high mortality due to its aggressive nature and tendency to spread (metastasize).
- A novel anti-EGFR antibody-endostatin fusion protein, αEGFR-E-P125A, was developed to target EGFR-expressing TNBC tumors, showing strong potential in reducing tumor cell motility and disruption of abnormal blood vessel formation (vasculogenic mimicry) in lab tests.
- In animal studies, αEGFR-E-P125A effectively inhibited tumor growth and metastasis, making it a promising approach for preventing the spread of TNBC due to its dual action against angiogenesis and tumor cell behavior
